Vinner-LF

General characteristics. Structure:

Active ingredient: 5 mg of a Vinpocetine (in terms of 100% of substance).

Excipients: potato starch, aerosil, talc, magnesium stearate, lactose.

The medicine which is actively applied at the diseases connected with disturbance of cerebral circulation. Improves cerebral circulation and, thereby, supply of a brain with oxygen and glucose; at the same time it is noted that strengthening of a blood-groove occurs, first of all, in those sites of a brain where vessels are narrowed.

Pharmacological properties:

Pharmacodynamics. Selectively improves blood supply of a brain and portability of cerebral ischemia. The mechanism of selective improvement of hemodynamic indicators of a brain blood-groove of a Vinpocetine is caused by direct spasmolytic myotropic action on brain vessels. Slightly reduces arterial pressure.

Strengthens regional blood circulation in an ischemic zone of a brain. A Vinpocetine, improving microcirculation in brain tissues, slows down aggregation of thrombocytes, reduces viscosity of blood. Improves portability hypoxia brain cells, strengthening aerobic process of utilization of glucose.

Stimulates as well anaerobic metabolism of glucose by braking of phosphodiesterase and stimulation of adenylatecyclase that leads to accumulation in cells of a brain of cyclic AMF. Increases the maintenance of catecholamines in a brain.

Indications to use:

- mental and neurologic symptoms of frustration of cerebral circulation of various origin (after a brain stroke, a brain injury or sclerous manifestations), such as memory disturbance, motive frustration, dizzinesses, headache;

- the alternating insufficiency and a spasm of brain vessels, ischemic damages of a brain, atherosclerosis of vessels of a brain;

- in the field of ophthalmology at obstruction of arteries of a retina and a choroid, at the degenerative changes of a macula lutea caused, first of all, by atherosclerosis or a vasomotor spasm at partial thromboses, the secondary glaucoma which arose owing to obstruction of vessels;

- in the field of an otiatria at age vascular or certain toxic (medicamentous) decreases in hearing, at dizzinesses of a labyrinth origin.

Route of administration and doses:

Accept inside 5 – 10 mg 3 times a day. A maintenance dose – 5 mg 3 times a day. Apply it is long. Improvement is observed usually in 1-2 weeks; a course of treatment - not less than 2 months.

Features of use:

With care appoint to patients with severe forms of arrhythmias, with stenocardia. ECG control in the presence of a syndrome of the extended interval of QT is recommended or at a concomitant use of the medicine promoting lengthening of an interval of QT.

At reception to consider existence of the lactose intolerance which is excipient of this medicine.

Side effects:

The Vinpocetine is safe medicine that was confirmed with the researches on safety assessment which were including data on tens of thousands of patients and showed that even those undesirable effects which arose most often did not vanish under category "often arising" according to MedDRA definition i.e. side effects with the greatest probability of emergence were registered with a frequency less than 1%. For this reason in tablets there is no category of frequency below "often arising".

The undesirable reactions arising against the background of reception of a Vinpocetine are listed below with division according to classes of systems and bodies and with the indication of frequency of emergence according to MedDRA terminology: often (> 1/100 - <1/10); infrequently (> 1/1000 - <1/100); seldom (> 1/10 000 - <1/1000); very seldom (<1/10 000), it is unknown (frequency cannot be determined by the data which are available for today).

Class of system of bodies MedDRA	Infrequently arising	Seldom arising	Very seldom arising
Disturbances from blood and lymphatic system		Leykotsitopeniya. Thrombocytopenia.	Anemia. Agglutination of erythrocytes.
Disturbances from immune system			Hypersensitivity
Disturbances of metabolism and food	Hypercholesterolemia	Loss of appetite. Anorexia. Diabetes mellitus.
Mental disorders		Sleeplessness. Sleep disorder. The hung-up excitability.	Euphoria. Depression.
Disturbances from a nervous system.	Headache.	Dizziness. Dysgeusia. Stupor. Hemiparesis. Drowsiness. Amnesia.	Tremor. Convulsions.
Disturbances from organs of sight		Papilledema	Conjunctiva hyperemia.
Disturbances from acoustic organs and a labyrinth	Dizziness.	Hyperacusia. Gipoakuziya. Sonitus.
Disturbances from heart		Ischemia/myocardial infarction. Angina of exertion. Bradycardia. Tachycardia. Premature ventricular contraction. Heartbeat.	Arrhythmia. Fibrillation of auricles.
Vascular disorders	Hypotension.	Hypertensia. Inflows. Thrombophlebitis.	Fluctuations of arterial pressure.
Disturbances from digestive tract	Discomfort in a stomach. Dryness in a mouth. Nausea.	Abdominal pain. Lock. Diarrhea. Dyspepsia. Vomiting.	Dysphagy. Stomatitis.
Pathology of skin and hypodermic cellulose		Erythema. Hyperhidrosis. Itch. Rash. Small tortoiseshell.	Dermatitis.
The general disturbances and reactions in a drug injection site		Adynamy. Indispositions. Feelings of heat.	Discomfort in a thorax. Hypothermia.
Results of inspection.	Lowering of arterial pressure.	Increase in arterial pressure. Increase in level of triglycerides in blood. Deprnessiya of ST segment on the electrocardiogram. Reduction / increase in quantity of eosinophils. Distinctions in activity of liver enzymes.	Reduction / increase in quantity of leukocytes. Decrease in level of erythrocytes. Reduction of time of formation of thrombin. Increase in body weight.

 

Interaction with other medicines:

Increases risk of hemorrhagic complications against the background of a geparinoterapiya. Strengthens action of anti-hypertensive means.

Contraindications:

Pregnancy, lactation and hypersensitivity to drug.

Overdose:

Symptoms: the overdose is followed by strengthening of side effects.

Treatment: gastric lavage, reception of absorbent carbon, symptomatic therapy.

Storage conditions:

To store in the place, unavailable to children, protected from light and moisture at a temperature not above 25 °C. Period of validity 3 years.

Issue conditions:

According to the recipe

Packaging:

On 10 tablets in a blister strip packaging. On 3, 5 or 6 blister strip packagings in a cardboard pack together with the application instruction.